Sponsors (22)
Introduced April 9, 2025 by Stephanie I. Bice · Last progress April 9, 2025
The bill centralizes and funds federal coordination, workforce development, and commercialization to accelerate biotechnology innovation and strengthen biosecurity, while raising taxpayer cost, concentrating executive authority, reducing some transparency, and creating privacy and safety risks that must be managed.
Scientists, researchers, and small biotech firms gain more coordinated federal R&D funding, joint solicitations, grants, and commercialization support that accelerate development of biotech products and create jobs.
Students, workers, and employers benefit from expanded workforce development, training, fellowships, and curriculum efforts that grow the domestic biotech talent pipeline and hiring opportunities.
Innovators and the public get a clearer single federal point of contact, website, and statutory definitions that make funding opportunities, regulatory pathways, and plain‑language guidance easier to find and apply.
Taxpayers will likely face increased federal spending to create and staff a new executive office, fund grants, centers, and ongoing program costs over multiple years.
The public and taxpayers lose transparency because exempting Initiative meetings from FACA removes routine public disclosure (participant lists, minutes) and raises risk of undisclosed outside influence.
Centralizing and sharing biological data increases privacy and misuse risks for patients, students, and research subjects if data protections fail or are unevenly applied.
Based on analysis of 6 sections of legislative text.
Creates a White House office and interagency committee to coordinate federal biotechnology strategy, R&D, data infrastructure, commercialization, workforce, and biosecurity across agencies.
Creates a White House National Biotechnology Coordination Office (NBCO) and an interagency committee to coordinate federal biotechnology activities across civilian, defense, health, agriculture, energy, space, and environmental missions. Requires designated agency leads to implement a national biotechnology strategy, support R&D, build data and commercial pathways, strengthen biosafety/biosecurity and workforce development, and assess foreign investment and supply-chain risks. The NBCO Director will advise the President and OMB, convene experts (exempt from the Federal Advisory Committee Act), and coordinate federal regulation and spending priorities; the Office and committee must be set up within 180 days of enactment.